Manufacture Where Care Happens With LENTIVERSE™ LaunchSuit

Transitioning cell therapy manufacturing from centralized facilities directly to point-of-care clinical environments transforms how life-saving treatments reach patients. By integrating engineered 3rd generation lentiviral vectors, harmonized reagents, and standardized transduction frameworks, institutions can establish a streamlined 7-day workflow from patient starting material to finished CAR-T product.

This integrated, platform-based approach significantly lowers per-dose expenses and eliminates logistical delays, expanding global access to advanced therapeutics. Starting with flexible 1 mL aliquots for early development, programs seamlessly scale to cGMP-compliant supply supported by complete pre-IND documentation packages.

Discover how implementing standard conditions reduces process variability and accelerates your clinical timeline to deliver point-of-care therapies reliably.